Investing.comDoubao · 实盘不做把握 7/10不做原因:标的无直接敞口
北京时间·🕒 发布 19:36:36·⟳ 抓取 19:37:04 +28s·⚡ 决策 10-12 19:39:02 +1m58s·15.1 天前
TG Therapeutics 公布 BRIUMVI 五年 MAIC 探索性分析，称残疾进展风险低于竞品，但属间接比较、非头对头证据
这是公司/伙伴资助的探索性间接比较（非随机头对头），证据等级低、不能改变处方或指南；且 TG Therapeutics 过去一年已多次发布更强的 BRIUMVI 五年/六年长期数据（含 JAMA Neurology 发表），本条为增量重复叙事，盘前股价反而下跌约1.6%，市场未给予正向重定价，无做多 edge；对竞品亦无实质做空依据。
📄 原文Investing.com↗ 原文
BRIUMVI shows lower disability progression vs competitors in MS study
By Investing.com Advertisement Advertisement BRIUMVI shows lower disability progression vs competitors in MS study Comp…
不做 TG Therapeutics（TGTX.US）
探索性、伙伴资助的间接比较（非头对头），证据等级低且无收入/标签增量；公司已多次发布更强五年/六年长期数据，边际信息重复；盘前股价约 -1.55% 未予正向定价，无做多 edge，也无做空催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BRIUMVI 五年 MAIC 显示残疾进展优于两款竞品，但属作者自述有局限的 unanchored 间接比较、伙伴资助，且公司已有多篇更强长期数据，边际信息有限；盘前 TGTX 下跌约1.6%，不构成可交易催化，回避。
消息传播链
- Investing.com 转述公司新闻稿，称五年 MAIC 显示 BRIUMVI 残疾进展风险低于 ocrelizumab/ofatumumab；文章为 AI 生成、编辑审核，非一手临床披露市场反应:TGTX 盘前约54.51美元、较前收55.37下跌约1.55%，盘前量极小
关键理由
- 名义上对 BRIUMVI 差异化有利的长期数据，但 MAIC 是最低等级比较证据，无法转化为处方/份额的近期增量
主要风险
- 若市场将其当作头对头优势炒作，短线可能情绪性走高，但缺乏直接比较研究支撑、易被解读为赞助方营销
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 invalidates
正文自述 unanchored MAIC 无法校正未测量差异、残余混杂不能排除、需直接比较研究证实；属低等级证据，削弱做多逻辑
检索:BRIUMVI MAIC indirect comparison limitations head-to-head criticism competitive risk TGTX 原文 ↗
先例如何影响了这次决策
对本次决策的影响:证据等级与重复叙事直接支持 AVOID，无需也不应据此设定 ENTER 的 tp/sl
方向:不足以构成先例：本条为探索性间接比较期刊发表，而非标签扩展、头对头阳性或新销售里程碑，缺乏可对齐的同类可交易事件
涨幅量级:无高相似对齐先例，不用任何数字校准止盈止损；盘前实际为负向反应，本身即说明市场不视为利好
形态:无样本判断见光死模式
工具执行结果 · 成功 2 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`briumvi 5-year matching-adjusted indirect comparison multiple sclerosis and related disorders publication | tg therapeutics briumvi ublituximab five-year maic disability progressio`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 2,106 ms
豆包搜索结果（原始查询:TG Therapeutics BRIUMVI five-year matching-adjusted indirect comparison ublituximab disability progression press release；API SearchType:web） - stock_quote 降级 stock_tools HTTP · 8,010 ms
{
原文全文
展开原文 · 7,631 字
BRIUMVI shows lower disability progression vs competitors in MS study By Investing.com
Advertisement
Advertisement
BRIUMVI shows lower disability progression vs competitors in MS study
Company News
Published
Oct 12, 2026, 07:36 AM
BRIUMVI shows lower disability progression vs competitors in MS study
View all comments (0)
0
BRIUMVI shows lower disability progression vs competitors in MS study
View all comments (0)
0
© Reuters
In this article:
TGTX
+
3.81%
NEW YORK -
TG
Therapeutics Inc. (
NASDAQ:TGTX
) announced Monday the publication of a five-year matching-adjusted indirect comparison evaluating BRIUMVI (ublituximab-xiiy) against ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis, according to a press release statement.
The analysis, published in Multiple Sclerosis and Related Disorders, used individual patient data from 545 BRIUMVI-treated participants in the Phase 3 ULTIMATE I and II trials and compared outcomes with published aggregate data from the Phase 3 OPERA I/II trials of ocrelizumab and ASCLEPIOS I/II trials of ofatumumab. BRIUMVI patient-level data were reweighted to align baseline characteristics with the respective comparator trial populations.
The findings showed BRIUMVI was associated with a 44% lower relative hazard of 24-week confirmed disability progression versus ocrelizumab and a 49% lower relative hazard versus ofatumumab. The estimated cumulative incidence of confirmed disability progression at 240 weeks was 9.3% for BRIUMVI versus 16.1% for ocrelizumab and 9.4% for BRIUMVI versus 17.9% for ofatumumab.
BRIUMVI demonstrated annualized relapse rates declining from 0.118 in Year 1 to 0.032 in Year 5 in the comparison with ocrelizumab, and from 0.116 to 0.030 in the comparison with ofatumumab.
The authors noted the findings should be interpreted within the inherent limitations of an unanchored matching-adjusted indirect comparison. The methodology cannot adjust for unmeasured differences between trials, and residual confounding cannot be excluded. The findings are considered exploratory and require confirmation in direct comparative studies.
The study was funded by Neuraxpharm, TG Therapeutics’ European commercialization partner for BRIUMVI.
BRIUMVI received approval from the U.S. Food and Drug Administration to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BRIUMVI shows lower disability progression vs competitors in MS study
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,708.60
+53.4
+0.10%
US 500
7,816.20
+4.7
+0.06%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.47
+0.63
+4.25%
Dollar Index
102.215
+0.193
+0.19%
Crude Oil WTI Futures
93.02
+1.17
+1.27%
Brent Oil Futures
106.10
+1.38
+1.32%
Natural Gas Futures
3.122
-0.098
-3.04%
Gold Futures
4,195.57
-20.73
-0.49%
Silver Futures
60.91
-0.138
-0.23%
Copper Futures
6.7733
+0.0813
+1.21%
US Soybeans Futures
1,283.63
-7.38
-0.57%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.07
-0.02
-0.01%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Goldman names 3 names to benefit as high-performance NAND tackles AI’s memory wall
By Investing.co
...
Oct 12, 2026
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
BRIUMVI shows lower disability progression vs competitors in MS study
Company News
Published
Oct 12, 2026, 07:36 AM
BRIUMVI shows lower disability progression vs competitors in MS study
View all comments (0)
0
BRIUMVI shows lower disability progression vs competitors in MS study
View all comments (0)
0
© Reuters
In this article:
TGTX
+
3.81%
NEW YORK -
TG
Therapeutics Inc. (
NASDAQ:TGTX
) announced Monday the publication of a five-year matching-adjusted indirect comparison evaluating BRIUMVI (ublituximab-xiiy) against ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis, according to a press release statement.
The analysis, published in Multiple Sclerosis and Related Disorders, used individual patient data from 545 BRIUMVI-treated participants in the Phase 3 ULTIMATE I and II trials and compared outcomes with published aggregate data from the Phase 3 OPERA I/II trials of ocrelizumab and ASCLEPIOS I/II trials of ofatumumab. BRIUMVI patient-level data were reweighted to align baseline characteristics with the respective comparator trial populations.
The findings showed BRIUMVI was associated with a 44% lower relative hazard of 24-week confirmed disability progression versus ocrelizumab and a 49% lower relative hazard versus ofatumumab. The estimated cumulative incidence of confirmed disability progression at 240 weeks was 9.3% for BRIUMVI versus 16.1% for ocrelizumab and 9.4% for BRIUMVI versus 17.9% for ofatumumab.
BRIUMVI demonstrated annualized relapse rates declining from 0.118 in Year 1 to 0.032 in Year 5 in the comparison with ocrelizumab, and from 0.116 to 0.030 in the comparison with ofatumumab.
The authors noted the findings should be interpreted within the inherent limitations of an unanchored matching-adjusted indirect comparison. The methodology cannot adjust for unmeasured differences between trials, and residual confounding cannot be excluded. The findings are considered exploratory and require confirmation in direct comparative studies.
The study was funded by Neuraxpharm, TG Therapeutics’ European commercialization partner for BRIUMVI.
BRIUMVI received approval from the U.S. Food and Drug Administration to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BRIUMVI shows lower disability progression vs competitors in MS study
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,708.60
+53.4
+0.10%
US 500
7,816.20
+4.7
+0.06%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.47
+0.63
+4.25%
Dollar Index
102.215
+0.193
+0.19%
Crude Oil WTI Futures
93.02
+1.17
+1.27%
Brent Oil Futures
106.10
+1.38
+1.32%
Natural Gas Futures
3.122
-0.098
-3.04%
Gold Futures
4,195.57
-20.73
-0.49%
Silver Futures
60.91
-0.138
-0.23%
Copper Futures
6.7733
+0.0813
+1.21%
US Soybeans Futures
1,283.63
-7.38
-0.57%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.07
-0.02
-0.01%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Goldman names 3 names to benefit as high-performance NAND tackles AI’s memory wall
By Investing.co
...
Oct 12, 2026
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
9034aba982· 2026-10-12 19:39 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前